In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

CVRx Funding Boost Will Sustain Barostim Heart Failure Device To US Launch

Executive Summary

US heart failure device manufacturer CVRx has scored a double hit by securing $113 million in funding in this flat investor climate and by being one of the first into the US FDA’s EAP, designed to help innovative technologies get faster access to market. CVRx’s much larger rivals are doubtless watching events with an uneasy mix of interest and concern.


Related Content

Device/Diagnostics Quarterly Deal Statistics, Q3 2016
Q&A With Nadim Yared: AdvaMed's Next Chair On Capital Formation And Global Challenges
CVRx’s Investment In HF And Wider Medtech Industry Set To Pay Off


Related Companies

Related Deals